Merck's Vaxneuvance Hits Key Endpoints in Infant Study
August 25 2021 - 7:00AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Wednesday said a Phase 3 study of its
Vaxneuvance 15-valent pneumococcal vaccine in infants met its key
immunogenicity and safety endpoints.
The Kenilworth, N.J., drugmaker, which last month received U.S.
Food and Drug Administration approval of the vaccine for adults,
said Vaxneuvance was generally well-tolerated in a second study,
with a safety profile generally comparable to the 13-valent
pneumococcal conjugate vaccine.
Merck's Phase 3 program for Vaxneuvance includes 16 studies in a
variety of populations who are at increased risk for pneumococcal
disease, including 10 investigating the vaccine for use in children
and infants.
The company said it plans to seek FDA approval for use of
Vaxneuvance in children before the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 25, 2021 07:51 ET (11:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024